Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities

Current Opinion in Lipidology

Volumn 21, Issue 4, 2010, Pages 312-318

  Kontush, Anatol ^a,b,c   Chapman, M John ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

apolipoprotein A I; fluidity; LCAT; lipid hydroperoxides; oxidative stress; oxidized LDL; oxidized phospholipids; PAF AH; PON1; rigidity

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LIPIDOME; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTEOME; ANTIOXIDANT; HIGH DENSITY LIPOPROTEIN;

ANTIOXIDANT ACTIVITY; ARTERY INTIMA; ARTERY WALL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; PROTEOMICS; REVIEW; ULTRACENTRIFUGATION; ANIMAL; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, HDL; OXIDATIVE STRESS;

EID: 77954956885     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833bcdc1     Document Type: Review

References (66)

1. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84:1381-1478.
2. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993-1007.
3. Rye K-A, Bursill CA, Lambert G, et al. The metabolism and antiatherogenic properties of HDL. J Lipid Res 2009; 50 (Suppl):S195-S200.
4. Garner B, Waldeck AR, Witting PK, et al. Oxidation of high density lipopro-teins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273:6088-6095.
5. Panzenbock U, Stocker R. Formation of methionine sulfoxide-containing specific forms of oxidized high-density lipoproteins. Biochim Biophys Acta 2005; 1703:171-181.
6. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41:1481-1494.
7. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117:746-756.
8. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14:55-61.
9. Thorngate FE, Rudel LL, Walzem RL, Williams DL. Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercho-lesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20:1939-1945.
10. Tangirala RK, Pratico D, FitzGerald GA, et al. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 2001; 276:261-266.
11. Raffai RL, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2005; 25:436-441.
12. Navab M, Hama LS, Van LB, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99:2005-2019.
13. Jordan-Starck TC, Witte DP, Aronow BJ, Harmony JA. Apolipoprotein J: a membrane policeman? Curr Opin Lipidol 1992; 1992:75-85.
14. Boisfer E, Stengel D, Pastier D, et al. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lipid Res 2002; 43:732-741.
15. Ostos MA, Conconi M, Vergnes L, et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21:1023-1028.
16. Ribas V, Sanchez-Quesada JL, Anton R, et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiathero-genic potential. Circ Res 2004; 95:789-797.
17. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3:144-153.
18. Kontush A, Chapman MJ. Functionally defective HDL: a new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 2006; 3:342-374.
19. Goyal J, Wang K, Liu M, Subbaiah PV. Novel function of lecithin-cholesterol acyltransferase. J Biol Chem 1997; 272:16231-16239.
20. Teiber JF, Draganov DI, La Du BN. Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 2004; 45:2260-2268.
21. Draganov DI, Teiber JF, Speelman A, et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46:1239-1247.
22. Kriska T, Marathe GK, Schmidt JC, et al. Phospholipase action of platelet-activating factor acetylhydrolase, but not paraoxonase-1, on long fatty acyl chain phospholipid hydroperoxides. J Biol Chem 2007; 282:100-108.
23. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acet-ylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J Biol Chem 2003; 278:3937-3947.
24. Connelly PW, Draganov D, Maguire GF. Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. Free Radic Biol Med 2005; 38:164-174.
25. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipopro-tein E-deficient mice. Circulation 2001; 103:2495-2500.
26. Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003; 44:927-934.
27. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25:923-931. (Pubitemid 40627835)
28. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473-480.
29. Goulinet S, Chapman MJ. Plasma LDL and HDL subspecies are heteroge-nous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. Arterios-cler Thromb Vasc Biol 1997; 17:786-796.
30. Zerrad-Saadi A, Therond P, Chantepie S, etal. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009; 29:2169-2175.
31. Christison JK, Rye KA, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res 1995; 36:2017-2026.
32. Girotti AW. Translocation as a means of disseminating lipid hydroperoxide-induced oxidative damage and effector action. Free Radic Biol Med 2008; 44:956-968.
33. Klimov AN, Kozhevnikova KA, Kuzmin AA, et al. On the ability of high density lipoproteins to remove phospholipid peroxidation products from erythrocyte membranes. Biochemistry (Mosc) 2001; 66:300-304.
34. Ferretti G, Bacchetti T, Moroni C, etal. Copper-induced oxidative damage on astrocytes: protective effect exerted by human high density lipoproteins. Biochim Biophys Acta 2003; 1635:48-54.
35. Ferretti G, Bacchetti T, Busni D, et al. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89:2957-2962.
36. Vila A, Korytowski W, Girotti AW. Spontaneous transfer of phospholipid and cholesterol hydroperoxides between cell membranes and low-density lipoprotein: assessment of reaction kinetics and prooxidant effects. Biochemistry 2002; 41:13705-13716.
37. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992; 89:1031 6-10320.
38. Proudfoot JM, Barden AE, Loke WM, etal. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 2009; 50:716-722.
39. Graham A, Hassall DG, Rafique S, Owen JS. Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. Atherosclerosis 1997; 135:193-204.
40. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000; 275:3957-3962.
41. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287.
42. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29:870-876.
43. Kontush A, Therond P, Zerrad A, etal. Preferential sphingosine-1- phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007; 27:1843-1849.
44. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23:1881-1888.
45. De Souza JA, Vindis C, Negre-Salvayre A, etal. Small, dense HDL3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2010; 14:608-620.
46. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.
47. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of prebeta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109:3215-3220.
48. Heinecke J. Presentation 772-the many transport functions of HDL. Circulation 2009; 120 (18-MeetingAbstracts).
49. Arbones-Mainar JM, Navarro MA, Carnicer R, etal. Accelerated atherosclerosis in apolipoprotein E-deficient mice fed Western diets containing palm oil compared with extra virgin olive oils: a role for small, dense high-density lipoproteins. Atherosclerosis 2007; 194:372-382.
50. Sparks DL, Davidson WS, Lund-KatzS, Phillips MC. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 1995; 270:26910-26917.
51. Curtiss LK, Bonnet DJ, Rye KA. The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry 2000; 39:5712-5721.
52. Mashima R, Yamamoto Y, Yoshimura S. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide-redu-cing proteins from human blood plasma. J Lipid Res 1998; 39:1133-1140.
53. Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89:4963-4971.
54. Kontush A, de Faria EC, Chantepie S, Chapman MJ. A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis 2005; 182:277-285.
55. Nobecourt E, Jacqueminet S, Hansel B, etal. Defective antioxidative activity of small, dense HDL particles in type 2 diabetes: Relationship to elevated oxidative stress and hyperglycemia. Diabetologia 2005; 48:529-538.
56. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19:2226-2233.
57. Kontush A, de Faria EC, Chantepie S, Chapman MJ. Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. Arterioscler Thromb Vasc Biol 2004; 24:526-533.
58. Patel S, Puranik R, Nakhla S, et al. Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis 2009; 204:424-428.
59. Balstad TR, Holven KB, Ottestad IO, et al. Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function. Clin Chim Acta 2005; 359 (1-2):171-178.
60. Persegol L, Verges B, Gambert P, Duvillard L. Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J Lipid Res 2007; 48:1396-1401.
61. Persegol L, Foissac M, Lagrost L, et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007; 50:2384-2387.
62. Persegol L, Verges B, Foissac M, et al. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2006; 49:1380-1386.
63. Van Lenten BJ, Navab M, Shih D, et al. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001; 11 (3-4):155-161.
64. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008; 118: 1259-1267.
65. Brock JW, Jenkins AJ, Lyons TJ, etal. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res 2008; 49:847-855.
66. Zhou H, Tan KC, Shiu SW, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol Dial Transplant 2008; 23:927-933.